Sanofi's investment in MeiraGTx could indicate an interest in the company's operations or products. However, the impact on Sanofi's stock price in the short term is uncertain as the investment represents a relatively small portion of Sanofi's overall capital. The potential benefits or returns from this investment may not be realized immediately.

The $30M investment from Sanofi provides MeiraGTx with additional capital, which could be used for various purposes such as research and development, expansion, or debt repayment. This could potentially lead to a positive impact on the company's stock price in the short term. Furthermore, the investment could signal potential future collaborations between the two companies.